Literature DB >> 2042392

Predicting the adsorption of proteins by aluminium-containing adjuvants.

S J Seeber1, J L White, S L Hem.   

Abstract

The adsorption of two model proteins, albumin and lysozyme, by boehmite or amorphous aluminium hydroxyphosphate adjuvants was studied. Electrostatic, attraction has a major role in adsorption. At physiological pH, boehmite, which has a point of zero charge above 7.35, extensively adsorbed albumin, which has an isoelectric point of 4.8, but was not effective in adsorbing lysozyme (isoelectric point, 11.0). Conversely, amorphous aluminium hydroxyphosphate (point of zero charge, 4.0) was effective in adsorbing lysozyme but adsorbed relatively little albumin. The results suggest that the selection of either boehmite or amorphous aluminium hydroxyphosphate as an adjuvant should be based in part on the isoelectric point of the antigen.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2042392     DOI: 10.1016/0264-410x(91)90154-x

Source DB:  PubMed          Journal:  Vaccine        ISSN: 0264-410X            Impact factor:   3.641


  22 in total

Review 1.  A rational, systematic approach for the development of vaccine formulations.

Authors:  Garry L Morefield
Journal:  AAPS J       Date:  2011-02-23       Impact factor: 4.009

2.  Working together: interactions between vaccine antigens and adjuvants.

Authors:  Christopher B Fox; Ryan M Kramer; Lucien Barnes V; Quinton M Dowling; Thomas S Vedvick
Journal:  Ther Adv Vaccines       Date:  2013-05

3.  Carrier properties of a protein derived from outer membrane protein A of Klebsiella pneumoniae.

Authors:  I Rauly; L Goetsch; J F Haeuw; C Tardieux; T Baussant; J Y Bonnefoy; N Corvaia
Journal:  Infect Immun       Date:  1999-11       Impact factor: 3.441

4.  Anthrax sub-unit vaccine: the structural consequences of binding rPA83 to Alhydrogel®.

Authors:  Andrei Soliakov; Ian F Kelly; Jeremy H Lakey; Allan Watkinson
Journal:  Eur J Pharm Biopharm       Date:  2011-09-22       Impact factor: 5.571

5.  Evaluation of alum-based adjuvant on the immunogenicity of salmonella enterica serovar typhi conjugates vaccines.

Authors:  Erman Tritama; Catur Riani; Indra Rudiansyah; Arip Hidayat; Siti Azizah Kharisnaeni; Debbie Sofie Retnoningrum
Journal:  Hum Vaccin Immunother       Date:  2018-02-21       Impact factor: 3.452

Review 6.  Advances in aluminum hydroxide-based adjuvant research and its mechanism.

Authors:  Peng He; Yening Zou; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2015       Impact factor: 3.452

7.  Disparate adjuvant properties among three formulations of "alum".

Authors:  Derek W Cain; Sergio E Sanders; Michael M Cunningham; Garnett Kelsoe
Journal:  Vaccine       Date:  2012-11-29       Impact factor: 3.641

Review 8.  Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability.

Authors:  Tanya Clapp; Paul Siebert; Dexiang Chen; LaToya Jones Braun
Journal:  J Pharm Sci       Date:  2010-08-25       Impact factor: 3.534

9.  Increasing the potency of an alhydrogel-formulated anthrax vaccine by minimizing antigen-adjuvant interactions.

Authors:  Allan Watkinson; Andrei Soliakov; Ashok Ganesan; Karie Hirst; Chris Lebutt; Kelly Fleetwood; Peter C Fusco; Thomas R Fuerst; Jeremy H Lakey
Journal:  Clin Vaccine Immunol       Date:  2013-08-28

10.  Considerable differences in vaccine immunogenicities and efficacies related to the diluent used for aluminum hydroxide adjuvant.

Authors:  Lin Lin; Ashraf S Ibrahim; Valentina Avanesian; John E Edwards; Yue Fu; Beverlie Baquir; Rebecca Taub; Brad Spellberg
Journal:  Clin Vaccine Immunol       Date:  2008-01-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.